Browse by Audience
MEMBER

Update Your Profile
Special Interest Groups (SIG)
Member Spotlights
IASP Connect
Join Now

RESEARCHER

PAIN
PAIN Reports
Pain Research Forum
Pain Researcher
Events

HEALTH CARE PROVIDER

Online Learning - PERC
Curricula
Graduate Opportunities
Treatment and Education Resources
Events

PATIENT & CAREGIVER

Resources for Living with Pain
Topic Pages
Free Videos
Events

PARTNER

Support IASP
Sponsor an Event
Become a Partner
Make a Donation

I am a
IASP Logo
Home I AM A Search Login

Papers of the Week

Home / Publications / Pain Research Forum / Papers of the Week / In migraine with previous treatment failures, eptinezumab safely reduced migraine days at 1 to 12 wk.

< BACK TO ARCHIVE


2022 Oct 04


Ann Intern Med


http://www.ncbi.nlm.nih.gov/pubmed/36191321?dopt=Abstract

In migraine with previous treatment failures, eptinezumab safely reduced migraine days at 1 to 12 wk.

Authors

In migraine with previous treatment failures, eptinezumab safely reduced migraine days at 1 to 12 wk.
Absher JR
Ann Intern Med. 2022 Oct 04.
PMID: 36191321.

Abstract

Ashina M, Lanteri-Minet M, Pozo-Rosich P, et al. Lancet Neurol. 2022;21:597-607. 35716692.
Read This Paper